Phenibutum

General characteristics. Structure:

Active agent: γ-amino-β-fenilbutirovy acid hydrochloride of 250 mg.

Pharmacological properties:

Nootropic means, represents gamma amino - beta phenyl-butyric acid a hydrochloride. Facilitates the GABA mediated transfer of nervous impulses in TsNS (direct impact on GABA receptors), renders also tranquilizing, psychogogic, antiagregantny and antioxidant action.
Improves a functional condition of a brain due to normalization of metabolism of fabrics and influence on cerebral circulation (increases the volume and linear speed of a brain blood-groove, reduces a tone of vessels of a brain, improves microcirculation, has antiagregantny effect). Promotes decrease or disappearance of feeling of alarm, tension, concern and fear, normalizes a dream, has some anticonvulsant effect.
Does not influence on well-cared and adrenoceptors.
Extends stage of latency and shortens duration and expressiveness of a nystagmus.
Reduces manifestations of an adynamy and vazovegetativny symptoms (including a headache, heavy feeling in the head, sleep disorders, irritability, emotional lability), increases intellectual working capacity.
Improves psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions).
At course reception increases physical and intellectual effeciency, improves memory, normalizes a dream; improves a condition of patients with motive and speech disturbances. At patients with an adynamy from the first days of therapy the health improves; increases interest and an initiative (motivation of activity) without sedative action and excitement. At use after heavy ChMT increases quantity of mitochondrions in perifocal areas and improves the course of biopower processes in a brain.
At neurogenic damages of heart and stomach normalizes processes of a peroksidation of lipids. Does not cause in people of advanced age load and excessive slackness, the weakening after-effect most often is absent. Improves microcirculation in eye tissues, reduces the oppressing influence of ethanol on TsNS. Malotoksichen.

Pharmacokinetics. Absorption is high, well gets into all body tissues and through GEB (about 0.1% of the entered drug dose, and at persons of young and advanced age in much bigger degree get into tissues of a brain). It is evenly distributed in a liver and kidneys. It is metabolized in a liver - 80-95%, metabolites pharmacological are inactive. Does not kumulirut. In 3 h it begins to be allocated with kidneys, at the same time concentration in tissue of a brain does not decrease and it is found in a brain during 6 h. About 5% are removed by kidneys in not changed look, partially - with bile.

Indications to use:

Asthenic and alarming and neurotic states, uneasiness, fear, neurosis of persuasive states, psychopathy. Stutter and tics at children, enuresis. An ischuria against the background of myelodisplasias. Sleeplessness and dreadful dreams at elderly people. Prevention of the alarming states arising before surgical interventions and painful diagnostic testings (premedication).
Menyer's disease, dizzinesses connected with dysfunctions of a vestibular analyzer of various genesis (including at an otogenic labyrinthitis, vascular and traumatic disorders); prevention of motion deseases at kinetoza.
Primary open angle glaucoma (as a part of a combination therapy).
As auxiliary therapy at treatment of alcoholism (for stopping of psychopathological and somatovegetativny frustration at an abstinence syndrome).
Treatment of predeliriozny and delirious states at alcoholism (in a combination with the standard disintoxication means).

Route of administration and doses:

Inside, irrespective of meal. The dose, frequency rate of reception and duration of treatment depend on indications, age of the patient, portability. The single dose for adults varies from 20 mg to 750 mg, for children – from 20 mg to 250 mg.

Features of use:

With care to apply at erosive cankers of a GIT, a liver failure.
At prolonged use it is necessary to control indicators of function of a liver and a picture of peripheral blood.
It is ineffective at the expressed motion desease phenomena (including pernicious vomiting, dizziness).
Influence on ability to driving of motor transport and to control of mechanisms
During treatment it is necessary to abstain from potentially dangerous types of activity requiring special attention and high speed of psychomotor reactions.

Side effects:

From TsNS: irritability strengthening, excitement, uneasiness, dizziness, headache, drowsiness.
From the alimentary system: nausea (at the first receptions).
Allergic reactions: skin rash, itch.

Interaction with other medicines:

Extends and strengthens action of somnolent, narcotic analgetics, antiepileptic, antipsychotic and protivoparkinsonichesky means.

Contraindications:

Hypersensitivity to Phenibutum.

Use at pregnancy and feeding by a breast
With care to apply at pregnancy, in the period of a lactation.

Use at abnormal liver functions
With care to apply at a liver failure.

Overdose:

Symptoms: drowsiness, nausea, vomiting, arterial hypotension, renal failure. At prolonged use of Phenibutum in a daily dose of 7-14 g development of a hepatotoxic action (including fatty dystrophy of a liver), eosinophilias is possible.
Treatment: gastric lavage, symptomatic and maintenance therapy.

Storage conditions:

To store in dry, protected from light, the place, unavailable to children, at a temperature up to 25 °C.

Issue conditions:

According to the recipe

Packaging:

Tablets on 20 pieces in packaging.